Cargando…
基于微阵列聚焦电泳的糖尿病血样临床阳离子交换高效液相色谱图中血红蛋白A(3)峰位置推测
Hemoglobin A(1c) (HbA(1c)) is a major component of glycated hemoglobin in human red blood cells. It has been proven to be a significant biomarker for the diagnosis of diabetes; its content in fresh red cells in diabetes blood reflects the average level of blood glucose over the previous three months...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Chromatography
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404208/ https://www.ncbi.nlm.nih.gov/pubmed/34677023 http://dx.doi.org/10.3724/SP.J.1123.2020.12033 |
Sumario: | Hemoglobin A(1c) (HbA(1c)) is a major component of glycated hemoglobin in human red blood cells. It has been proven to be a significant biomarker for the diagnosis of diabetes; its content in fresh red cells in diabetes blood reflects the average level of blood glucose over the previous three months. Thus, HbA(1c) level has been used for the assessment of long-term glycemic control in diabetes; the level of 6.5% HbA(1c) has been certified as a critical cut-off for the diabetes diagnosis. The current commonly used method for HbA(1c) quantification is based on cation-exchange high performance liquid chromatography (CX-HPLC). The method has advantages such as high stability, rapidity, and automation, but there are still some unidentified peaks of Hb species in CX-HPLC (VARIANT Ⅱ system); in particular, the presence of HbA(3) (a glutathiolated Hb) affects the accurate determination of HbA(1c). HbA(3) is usually present in healthy adult blood samples at 2%-4%, but the concentration of HbA(3) increases due to the protection of erythrocytes from oxidation, resulting in decreased HbA(1c). However, the relative location of the HbA(3) peak in the CX-HPLC clinical chromatogram has not been established. To address this issue, we extracted Hb species from fresh blood samples obtained from a hospital in an anaerobic environment to avoid possible redox reactions of Hb and glutathione. After the extraction, the Hb samples were analyzed using two methods: a low-resolution CX-HPLC (5/50 mm column) currently used for diabetes diagnosis and a high-resolution cationic exchange HPLC (Mono-S 5/50 mm column), to identify the peak corresponding to HbA(3). The CX-HPLC analysis of fresh blood samples indicated that the unknown peak P3 located between HbA(1c) and HbA(0) peaks corresponded to the HbA(3) peak between HbA(1c) and HbA(0) in the Mono-S-HPLC. Microarray isoelectric focusing (IEF) was used for the micro-preparation of HbA(3), HbA(1c), and HbA(0) in healthy blood samples; then, the micro-prepared species of HbA(3), HbA(1c), and HbA(0) were individually identified via Mono-S-HPLC. The results of the CX-HPLC, Mono-S-HPLC, and microarray IEF experiments indicated that the P3 peak might correspond to HbA(3). To confirm this, glutathiolated Hb samples were synthesized via acetylphenylhydrazine and analyzed using both the Mono-S- and CX-HPLC systems. The results showed that the content of both glutaminated hemoglobin of HbA(3) in Mono-S-HPLC and P3 in CX-HPLC increased, implying the peak of P3 with the retention time of 1.50 min in CX-HPLC was the peak corresponding to HbA(3) in Mono-S-HPLC and microarray IEF. Based on the above experiments and our previous results, the influence of HbA(3) on both the analysis of HbA(1c) in blood samples and the diabetes diagnosis needs to be considered and discussed. The study results are significant for the tentative assignment of peak P3 and for offering more information on diabetes diagnosis using CX-HPLC in the clinical setting. |
---|